关键信息
-
基因名
Chrac1
- 应用
-
别名
(CHRAC-1)(DNA polymerase epsilon subunit p15)(NF-YC-like protein)(YC-like protein 1)(YCL1)
-
种属
Mouse
-
表达系统
E. coli
-
标签
N- His & C- Myc
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9JKP8
-
表达区间
2-129aa
-
分子量
21.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Chrac1, a member of the Chimeric Receptor and Cytokine Superfamily, has garnered significant attention in recent years due to its potential roles in immune regulation and cellular signaling. As a restructured protein, Charc1 plays a crucial role in mediating interactions between immune cells, influencing both innate and adaptive immunity. Research has indicated that this protein may be implicated in various pathological conditions, including autoimmune diseases and cancers, where its expression levels and activity could affect disease progression and response to therapies. The ability to produce recombinant Charc1 protein has enabled scientists to explore its structural properties, functional mechanisms, and potential therapeutic applications in more detail. For instance, studies utilizing recombinant Charc1 are crucial for understanding its ligand interactions and downstream signaling pathways, which can reveal novel targets for drug development. Furthermore, the exploration of Charc1 as a biomarker in clinical settings is an emerging area of interest, potentially aiding in patient stratification and personalized medicine. Given the complexity of immune responses, ongoing research into recombinant Charc1 will continue to contribute to our understanding of its biological significance and therapeutic potential.
